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Summary.
For many medical conditions several treatment options may be available for treating pa-
tients. We consider evaluating markers based on a simple treatment selection policy that
incorporates information on the patient’s marker value exceeding a threshold. For exam-
ple, colon cancer patients may be treated by surgery alone or surgery plus chemother-
apy. The c-myc gene expression level may be used as a biomarker for treatment selec-
tion. Although traditional regression methods may assess the effect of the marker and
treatment on outcomes, it is appealing to quantify more directly the potential impact on
the population of using the marker to select treatment. A useful tool is the selection im-
pact (SI) curve proposed by Song and Pepe (2004, Biometrics 60, 874–883) for binary
outcomes. However, the current SI method does not deal with continuous outcomes,
nor does it allow to adjust for other covariates that are important for treatment selection.
In this paper, we extend the SI curve for general outcomes, with a specific focus on
survival time. We further propose the covariate specific SI curve to incorporate covari-
ate information in treatment selection. Nonparametric and semiparametric estimators
are developed accordingly. We show that the proposed estimators are consistent and
asymptotically normal. The performance is illustrated by simulation studies and through
an application to data from a cancer clinical trial.
1. INTRODUCTION
Selecting an appropriate treatment for patients is important when several treatment options
are available. Treatment selection may be facilitated by evaluating clinical characteristics or
biomarker measurements of patients at diagnosis. The rapidly expanding biotechnologies,
including gene expression arrays and imaging modalities, show promises in providing useful
biomarkers that may be used for selection of the optimal treatment of disease (Elmer-Dewitt
et al., 2001). For example, patients with colon cancer can be treated by surgery alone or
surgery plus chemotherapy. Surgery alone is less invasive and less expensive than surgery
plus chemotherapy, but it may be less effective as well, at least for some patients. It is
desirable to identify the patients who may benefit more from surgery based on biomarkers.
A possible useful biomarker is the c-myc gene, which is overexpressed in approximately 70%
Address for correspondence: Xiao Song, Department of Biostatistics and Epidemiology, College
of Public Health, University of Georgia, Paul Coverdell Center, Room 129c, Athens 30602, USA.
E-mail: xsong@uga.edu
Hosted by The Berkeley Electronic Press
2 X. Song and X.H. Zhou
of human colonic tumors (Erisman et al., 1988). Based on a study conducted by the Eastern
Cooperative Oncoloty Group (ECOG), Augenlicht et al. (1997) suggested that the c-myc
gene may be of clinical prognostic importance in patients with colon cancer. Using a subset
of the cases from this clinical trial, Li and Ryan (2006) indicated that there is an interaction
between the c-myc gene expression level and the two treatments on overall survival and
disease progression free survival. Using the same dataset, we estimated the overall survival
and the disease progression free survival by treatment and c-myc gene expression level.
Figure 1 shows the Kaplan-Meier estimates of the disease progression survival for the four
combinations of the two treatments and whether the c-myc gene expression level exceeding
1.05, the 25% sample percentile. Although surgery plus chemotherapy seems prolonging
disease progression free survival better than surgery alone for patients with c-myc level >
1.05, it is not that clear which treatment is better for patients with c-myc level ≤ 1.05.
The Kaplan-Meier estimates for the overall survival show a similar pattern (not shown).
This motivated us to assess using the c-myc gene expression level for treatment selection
for colon cancer patients.
In clinical protocols, treatment selection is often based on whether a marker value ex-
ceeds a threshold. Some common examples include serum creatine > 1.3 mg/dL, cholesterol
> 200 mg/dL, and serum PSA > 4.0 ng/mL. As an analogy, we consider selection of surgery
alone versus chemotherapy plus surgery based on c-myc level exceeding a threshold. To eval-
uate such policies, Song and Pepe (2004) proposed a graphical tool, the selection impact
(SI) curve, for selection between two treatments based on binary response rate using a
biomarker. Let A = 0 denote one treatment and A = 1 denote the other. The outcome T
is dichotomous denoting success (T = 1) or failure (T = 0) in curing a disease. Let Y be a
continuous biomarker and larger values of Y are potentially associated with better perfor-
mance of treatment 1 versus 0 (Y can be recoded if necessary to achieve this ). Consider
the following treatment policy that determines which treatment the patient receives based
on a patient’s marker measure Y exceeding a threshold:
if Y > c , select treatment A = 1;
if Y ≤ c , select treatment A = 0, (1)
The population response (success) rate of the outcome corresponding to this policy is
θ(v) = Pr{T = 1| treatment policy (1) }
where v = Pr[Y ≤ c] is the proportion of subjects with the marker value below c and hence
assigned to treatment 0. That is, θ is the proportion of subjects in the population who
respond if the treatment policy in effect is to assign a subject to treatment 1 if his marker
value exceeds c but to assign him to treatment 0 otherwise. Observe that when c = −∞ or
equivalently v = 0, the policy is that all patients receive treatment 1 and none receive 0,
while for c =∞ or equivalently v = 1 all patients receive treatment 0. As c increases from
−∞ to ∞, the proportion of subjects assigned to treatment 0 increases from 0 to 1. There
are two reasons for defining θ as a function of quantile v. First, in evaluating a treatment
policy of this sort, it will be important to know the fractions of patients potentially assigned
to treatment A = 0 versus A = 1 by the policy, 1−v and v, respectively. Second, the display
on this scale allows one to compare policies based on different markers. In particular, even
if the markers are measured in different units, we can still compare the treatment policies
at a common percentile v, the larger θ(v) the better. The same idea has been adopted for
the receiver operative curve (ROC), which is widely used in evaluation of diagnostic tests
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(Zhou, et al., 2002; Pepe, 2003). When the two treatments are comparable in all other
aspects including cost and side effects, then the optimal threshold maximizes the SI curve
θ(v) such that the overall success rate achieves the maximum. As illustrated in Figure 2,
based on the biomarker Y1, the best criteria would be to assign 40% patients to treatment
0 whose biomarker value is less than the 40% percentile, while Y3 indicates it would be
best to assign all patients to treatment 1. Based on the biomarker Y2, for any v between
0 and 0.4, the success rate would be the same if we assign patients to treatment 0 whose
biomarker value falls below the vth percentile. However, if treatment 1 is more invasive or
more expensive, we may want to assign 40% patients to treatment 0 such that the overall
success rate achieves the maximum. Comparing the three biomarkers, it is obviously that
policy based on Y1 achieves the best success rate.
The SI curve is essentially a curve of the population response rate versus the percentile
threshold. Compared to traditional regression models, this approach has the advantage of
quantifying more directly the potential impact on the population of using the biomarker
to select treatment. Specifically, we may choose an optimal threshold based on the the
SI curve. However, there is a need for further improvement for wider applicability. First,
the current SI curve methodology considers only binary outcomes. It cannot be applied to
continuous outcomes such as survival time, which is frequently encountered in practice. For
example, in the ECOG study (Li and Ryan, 2006), the outcome of interest is the overall
survival time and the disease progression free survival of the colon cancer patients. It may
sometimes be desirable to select treatment based on a utility measure that incorporates
notions of cost and benefit when those factors differ for the two treatments. Second, the
current SI curve does not allow to adjust for other covariates, which may contain additional
important information for treatment selection. For colon cancer patients, the c-myc gene
may be indicative for which patients are likely to benefit more from surgery alone. The effect
of c-myc gene may be further impacted by covariates like gender and stage of cancer. For
example, the optimal threshold for c-myc gene expression level may be different for patients
with different covariate values. For example, Figures 3(a) and (b) show the Kaplan-Meier
estimates of disease progression free survival by treatment and c-myc gene expression level
above or below 1.05 for females and males separately. For either females or males with
c-myc level > 1.05, surgery plus chemotherapy seems better than surgery alone in terms of
prolonging disease progression free survival. However, for patients with c-myc level ≤ 1.05,
females seem benefited more from surgery while it is not clear which treatment is better for
males. In addition, the SI curve methodology was not applied to any real dataset in Song
and Pepe (2004). It is of great interest to demonstrate this method in real applications such
as the ECOG study.
To overcome the limitations of the current SI curve methodology, we generalize the
current SI curve definition in two steps. First, we propose the SI curve for general outcomes
for evaluating markers on treatment selection; Second, we extend the SI curve to adjust for
covariates. In this paper, we focus specifically on survival time, which is the outcome of
interest in the ECOG data and is more challenging compared to discrete and continuous
outcomes without censoring. The same technique can be easily adapted to the latter with
only minor modifications. We propose the SI curve based on the mean restricted survival
time up to a given time L. The reason of using mean restricted survival time is to avoid
the infeasibility of estimating the mean unrestricted survival time when censoring exists,
that is, the mean unrestricted survival time may not be estimated if the largest observed
survival time is censored without some tail correction on the estimated survival function
(Klein and Moeschberger, 2003). The technique of restricting survival time has been used
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previously in estimating the mean lifetime and quality-adjusted lifetime (e.g., Zhao and
Tsiatis, 1999; Chen and Tsiatis, 2001). The restricted survival time has also been widely
used in practice, for example, in cancer statistics, five year survival has been commonly used.
Due to the existence of censoring, the inference is more challenging than the binary case. A
nonparametric estimator is proposed to estimate the SI curve with no model assumptions
on survival time. To adjust for covariate effects, we further propose the covariate specific
SI curve and develop semiparametric estimators based on the proportional hazards model.
Asymptotic properties of the estimators are derived using empirical process and U-process
theories. The approach can be adapted to uncensored continuous outcomes with some
modifications.
This paper is organized as follows. In Section 2, we define the SI curve for survival time.
develop the nonparametric estimator and derive its asymptotic properties. In Section 3, we
define the covariate specific SI curve. We further derive the semiparametric estimators and
their asymptotic properties. The finite sample performance of these estimators is assessed
via simulation studies in Section 4 and illustrated by application to the ECOG data in
Section 5. The paper concludes with discussions in Section 6.
2. SELECTION IMPACT CURVE
2.1. Definition
We extend the SI curve to a general outcome T , that is, T can be either discrete or contin-
uous. We define the SI curve as
θ(v) = E {T |treatment policy (1)}
Here v = Pr[Y ≤ c] is the proportion of patients assigned to treatment 0 under policy
(1). The SI curve considered in Song and Pepe (2004) is a special case of (2) when T is
dichotomous. In this paper, we focus on SI curve for survival time hereafter.
Using the notion of potential responses (Rubin 1974, 1978; Holland, 1986), for a = 0, 1,
we define T a as the survival time if a patient receives treatment A = a. It is impossible to
observe T 0 and T 1 on the same patient; instead, we can only observe T = AT 1+(1−A)T 0.
Let T ∗a = min(T a, L), be the corresponding restricted survival time by time L. Similarly,
T ∗0 and T ∗1 can not be observed on the same patient and only T ∗ = AT ∗1 + (1−A)T ∗0 is
observable. Both T and T ∗ are subject to censoring. We define the SI curve as the mean
restricted survival time corresponding policy (1), that is,
θ(v) = E {T ∗ |treatment policy (1)}
= (1− v)E {T ∗1 |Y > yv }+ vE {T ∗0 |Y ≤ yv } . (2)
When the two treatments are comparable, the optimal threshold maximizes θ(v). Otherwise,
a utility measure incorporating the survival time, cost and side effects can be used. We
illustrate an application of a simple utility measure in Section 5.
2.2. Estimation
We now consider estimation of θ(v) using data obtained from a randomized trial where
the failure time is subject to censoring. Let C denote the censoring time. The observed
survival data consist of X = min(T,C) and ∆ = I(T ≤ C). Suppose the observations
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(Xi,∆i, Yi, Ai), i = 1, . . . , n, are an i.i.d. sample from the distribution of (X,∆, Y, A).
We make the following assumptions: (i) patients enrolled in the trial are a simple random
sample from the population of interest; (ii) the treatment assignment for patients in the
trial does not depend on his marker value, that is, Ai and Yi are independent.
Note that (2) can be rewritten as
θ(v) = (1− v)
∫ L
0
S(1)(t, yv)dt+ v
∫ L
0
S(0)(t, yv)dt,
where S(1)(t, y) = P (T ≥ t|A = 1, Y > y) and S(0)(t, y) = P (T ≥ t|A = 0, Y ≤ y).
Therefore, an estimator of θ(v) can be obtained by substituting estimators for S(a)(t, y)
(a = 0, 1) and yv. Here we use the Kaplan-Meier estimator of S(a)(t, y),
Sˆ(a)(t, y) =
t
0
{
1− N
(a)
i (ds, y)
R
(a)
i (s, y)
}
,
where is the product integral notation, N (1)i (t, y) = I(Xi ≤ t,∆i = 1, Ai = 1, Yi > y),
N
(0)
i (t, y) = I(Xi ≤ t,∆i = 1, Ai = 0, Yi ≤ y), R(1)i (t, y) = I(Xi ≥ t, Ai = 1, Yi > y), and
R
(0)
i (t, y) = I(Xi ≥ t, Ai = 0, Yi ≤ y), N (a)i (ds, y) = N (a)i (s, y) −N (a)i (s−, y). To estimate
yv, we use the nonparametric estimator yˆv = Fˆ−1Y (v), where FˆY (y) = n
−1∑n
i=1 I(Yi ≤ y)
is the empirical distribution of Y . Thus an estimator of θ(v) can be written as
θˆ(v) = (1− v)
∫ L
0
Sˆ(1)(t, yˆv)dt+ v
∫ L
0
Sˆ(0)(t, yˆv)dt.
This is a nonparametric estimator. It does not require any parametric assumptions on
the survival time and the biomarker. Moreover, it is invariant to any monotone increasing
transformation of the biomarker.
Now we derive the asymptotic properties of θˆ(v) using empirical process theory. The
idea is to first show that n1/2
{
Sˆ(a)(t, y)− S(a)(t, y)
}
converges to a Gaussian process under
some regularity conditions. Since θˆ(v) is a composite function of Sˆ(0), Sˆ(1) and FˆY , the
asymptotic distribution of θˆ(v) is then derived by the functional delta method (van der
Vaart and Wellner 2000, chap. 3.9). Specifically, we can show that n1/2
{
θˆ(v)− θ(v)
}
converges to a Gaussian process. The details of the asymptotic distribution and the proof
are given in Appendix A.
The covariance formula for θˆ(v) contains the density function of Y and the derivative
of the cumulative hazard functions of T conditional on (A = 1, Y > y) or (A = 0, Y ≤ y).
Usually smoothing techniques are needed to estimate these quantities. In applications, to
avoid the complexity of the smoothing approaches, for simplicity, we use the bootstrap
method to calculate the standard error and confidence band for θ(v). This is justified
by the empirical process theory for the bootstrap given in van der Vaart and Wellner
(2000, §3.9.3). Let Θ = {(Xi,∆i, Yi, Ai) : i = 1, . . . , n} be the observed data set, and
ΘB be the Bth resampling bootstrap dataset, where B = 1, . . . ,M . Let θˆB(v) be the
estimator based on ΘB . Then supv∈[p,q] |θˆB(v)−θˆ(v)| given Θ is asymptotically equivalent to
supv∈[p,q] |θˆ(v)−θ(v)|, 0 < p < q < 1. Let cα be the 1−α quantile of supv∈[p,q] |θˆB(v)−θˆ(v)|,
then a level 1− α confidence band for θ(v) is (θˆB(v)− cα, θˆB(v) + cα). The standard error
of θˆ(v) can be estimated by the standard deviation of {θˆB(v) : B = 1, . . . ,M}.
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3. COVARIATE SPECIFIC SELECTION IMPACT CURVE
So far, we have considered treatment selection based only on the biomarker. There are
situations that covariates other than the biomarker may impact treatment selection. Thus
it is important to adjust for such covariates. For example, if we use c-myc gene expression
level to select patients for surgery alone or surgery plus chemotherapy, we may want to
adjust for sex. If the covariates are discrete, it is possible to consider a separate SI curve
for each covariate combination. However, this will not work when there exist continuous
covariates. In addition, even if all covariates are discrete, the sample size for some covariate
combination may be too small to obtain a reliable SI curve estimate. It is noticeable that
the SI curve bears some similarities to the ROC curve used to evaluate diagnostic tests
based on a biomarker (Pepe 2000). To account for covariate effects, the ROC curve has
been extended to the covariate specific ROC curve (Zhou et al, 2002; Pepe, 2003). This
motivates us to propose the covariate specific SI curve by analogy to the covariate specific
ROC curve.
3.1. Definition
Let Z denote the vector of K covariates that may impact the treatment selection other than
the biomarker. To incorporate the covariates, we consider the following treatment policy
given Z = z:
if Y > yv,z , select treatment A = 1;
if Y ≤ yv,z , select treatment A = 0. (3)
Here yv,z is the vth quantile of the conditional distribution of Y given Z = z. The corre-
sponding covariate specific SI curve is defined as
θ(v|z) = E {T ∗ |treatment policy (3)}
= (1− v)E {T ∗1 |Y > yv,z,Z = z}+ vE {T ∗0 |Y ≤ yv,z,Z = z} . (4)
This definition is general to any outcomes, include binary and continuous outcomes. It
reduces to the unadjusted SI curve given in (2) when there is no covariate.
The covariate specific SI curve considers treatment selection conditional on the covariate
Z, which may be different for various values of Z. It provides a useful tool for policy makers
to choose different biomarker thresholds based on the values of Z.
3.2. Estimation
Now we consider estimation of θ(v|z) using data obtained from randomized trials, which sat-
isfies condition (i) and (ii) described in Section 2.2 and (iii)′ A is independent of Y given Z.
Suppose we have independent and identically distributed observations (Xi,∆i, Yi, Ai,Zi),
i = 1, . . . , n.
With some simple algebra, it can be shown that (4) can be rewritten as
θ(v|z) =
∫ 1
v
∫ L
0
S(t|u, z, 1)dtdu+
∫ v
0
∫ L
0
S(t|u, z, 0)dtdu, (5)
where S(t|u, z, a) = P{T ≥ t|Y = yu,z,Z = z, A = a}. An estimator of θ(v|z) can be
obtained based on (5).
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Assume that the hazard of failure follows the proportional hazards model
λi(t|Vi,Zi, Ai) = λ0(t) exp
[
βT0 g {Vi,Zi, Ai}
]
, (6)
where Vi = FY |Z(Yi|Zi), FY |Z(·|z) is the conditional distribution function of Y given
Z = z, and g(v,z, a) is a known r-dimensional function. It is useful to write the model in
terms of Vi, since θ(v) is considered a function of v for the reasons mentioned earlier. For
example we might use the model
λi(t|Vi,Zi, Ai) = λ0(t) exp
[
β1D(Vi,Zi) + βT2 Zi + β3Ai + β4D(Vi,Zi)Ai
+βT5 D(Vi,Zi)Zi + β6D(Vi,Zi)Ai + β
T
7 D(Vi,Zi)ZiAi
]
,
where D(v, z) is a function of v and z. When D(v, z) = F−1Y |Z(v|z), D(vi,Zi) is just the
biomarker Yi. Further assuming that FY |Z(·|z) is known, based on (5), we can estimate
θ(v|z) by
θ˜(v|z) =
∫ 1
v
∫ L
0
Sˆ(t|u, z, 1)dtdu+
∫ v
0
∫ L
0
Sˆ(t|u,z, 0)dtdu,
where
Sˆ(t|v, z, a) = exp
{
−Λˆ0(t) exp
(
βˆT g(v,z, a)
)}
is an estimator for the survival function S(t|v,z, a), βˆ is the partial likelihood estimator of
β0, and Λˆ0(t) is the Breslow estimator of the baseline cumulative hazard function Λ0(t).
In practice FY |Z is usually unknown. We assume the conditional distribution of Y given
Z following the semiparametric model (Pepe, 1998; Heagerty and Pepe, 1999),
FY |Z(y|z) = h(y − γT0 z), (7)
where h(·) is an unknown distribution function. The estimator γˆ of γ0 can be obtained by
solving
n∑
i=1
(Yi − γTZi)Zi = 0.
The function h(y) can be estimated by
hˆ(y; γˆ) = n−1
n∑
i=1
I(Yi − γˆTZi ≤ y).
Let β˜ be the solution to the partial likelihood estimating equation with FY |Z(y|z) replaced
by hˆ(y− γˆTz, γˆ) and Λ˜0(t) be the corresponding Breslow estimator of Λ0(t). An estimator
of θ(v|z) is
θ˜∗(v|Z) =
∫ L
0
∫ 1
v
S˜(t|v, z, 1)dudt+
∫ L
0
∫ v
0
S˜(t|v, z, 0)dudt,
where
S˜(t|v, z, a) = exp
{
−Λ˜0(t) exp
(
β˜T g(v, z, a)
)}
.
Note that both θ˜ and θ˜∗ can also be used in the case of no covariates. Since these estimators
are semiparametric estimators, they are more efficient than the nonparametric estimator
Hosted by The Berkeley Electronic Press
8 X. Song and X.H. Zhou
θˆ under the correct model assumptions. However, if the model assumptions are violated,
inference based on these estimators can be misleading. We may need to transform the
biomarker appropriately to assure that the proportional hazards assumption holds. In
contrast, the nonparametric approach is invariant to monotone increasing transformations.
Under some regularity conditions, we can show that both n1/2
{
θ˜(v|z)− θ(v|z)
}
and
n1/2
{
θ˜∗(v|z)− θ(v|z)
}
converge to zero-mean Gaussian processes. The derivation is in-
volved with application of empirical process and U-process theories. The details of the
asymptotic distribution and the proof are given in Appendix B. A consistent estimator for
the variance of θ˜(v|z) is given in equation (B.4), which involves complex integrals. The
variance formula for θ˜∗(v) is even more complicated and involves the derivative of the un-
known function h(·). In practice, by analogy to the nonparametric case, we can use the
bootstrap method to compute estimates of the standard errors and confidence bands for
θ˜(v|z) and θ˜∗(v|z).
4. SIMULATION STUDIES
Simulation studies were conducted to assess the finite sample properties of the estimators.
We first considered the simple case of no covariates when both the nonparametric and
semiparametric estimators can be used. We generated data for 300 and 600 patients in a
randomized trial with P[A = 1] = 0.5. The marker Y was generated from the standard
normal distribution. The survival time was generated according to the proportional hazards
model (6) with g(v, z, a) = (v, a, va)T , β = (−4,−2, 1)T , and λ0(t) = 0.1. Censoring time
was generated from an exponential distribution with mean 30 and truncated at 20, leading
to a censoring rate of about 30%. Consider L = 15, and the SI curve is shown in Fig. 4.
We estimated the SI curve using θˆ, θ˜ and θ˜∗ for 500 simulated data sets. The estimated
standard errors were computed by the bootstrap method using 100 resampled data sets for
all the estimators. For each estimator, the 95% Wald confidence intervals were calculated.
Table 1 presents the results for v = 0.1, . . . , 0.9. All the estimators exhibit negligible bias,
and the standard errors track the true standard deviations of the estimators well. The
coverage probabilities are close to their nominal levels. As expected, θ˜∗ is less efficient than
θ˜ because the true FY is used for the former while FY is estimated for the latter, but the
efficiency loss is small. Moreover, θ˜∗ is more efficient than the nonparametric estimator θˆ
as expected.
To investigate the robustness of the estimators, we also conducted simulations under sim-
ilar scenarios as above except that the survival time was generated from a gamma distribu-
tion with the shape parameter equal to 4 and the scale parameter equal to {5λi(t, Yi,Zi)}−1,
where λi(t, Yi,Zi) is the hazard in the simulation above. In this case, the survival model is
misspecified for the semiparametric estimators. The results are shown in Table 2. The non-
parametric estimator θˆ still works well while the semiparametric estimators are obviously
biased with poor coverage probabilities for the confidence intervals.
We then considered the case when a covariate Z was included. The covariate Z
was generated from a standard normal distribution. The biomarker Y equals Z plus a
standard normal error. The survival time followed the proportional hazards model (6)
with g(v, z, a) = (v, a, z, va, vz, az, vaz)T , β = (1,−0.7,−0.1,−0.9,−0.3, 0.8,−0.9), and
λ0(t) = 0.2. Censoring time was generated from an exponential distribution with mean 20
and truncated at 8, leading to a censoring rate of about 30%. Consider L = 5 and the
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covariate SI curves for z = −1, 0, 1 are shown in Fig. 5. For 500 simulated datasets with
n = 200 and 400, We estimated the covariate specific SI curves for 500 simulated datasets
with n = 200 and 400 using θ˜ and θ˜∗. The results in Table 3 show similar patterns as above
and both estimators work well.
In summary, the nonparametric estimator θˆ is robust while the semiparametric estima-
tors θ˜∗ and θˆ depend on the correct specification of the models. Obvious deviances between
these estimators may indicate violation of the model assumptions for the semiparametric
estimators. We recommend using the nonparametric estimator when there is no covariates.
Extension of the semiparametric estimators to more flexible models is discussed in Section 6.
5. APPLICATION
As an illustration, we applied the proposed approaches to a subset of the ECOG clinical trial,
which was analyzed by Li and Ryan (2006). In this subset, disease progression free survival
and c-myc expression level was measured on 92 patients randomized to receive surgery alone
or surgery plus chemotherapy, among which 47 were males and 45 were females. We are
interested in assessing whether the c-myc expression level can be used to select patients for
surgery alone versus surgery plus chemotherapy. We estimated the SI curve using both the
nonparametric and semiparametric methods. For the semiparametric approach, we included
log c-myc expression level Y , treatment indicator A = I(surgery plus chemotherapy) and
their interaction in the the proportional hazards model. This model was also used in Li and
Ryan (2006). This corresponds to g(v, z, a) = (v, a, va)T in the proportional hazards model
(6). We consider the mean disease progression free survival time restricted to five years.
Since the distribution FY (y) is unknown, we estimated the SI curve using the estimators
θˆ(v) and θ˜∗(v). The estimates and the 95% pointwise confidence intervals and simultaneous
confidence bands are shown in the left panel of Figure 6. The semiparametric estimate
is essentially a smoothed version of the nonparametric estimate, which indicates that the
corresponding model assumptions are appropriate for this dataset. The estimated SI curves
seem to decrease with v. That is, assigning all patients to surgery plus chemotherapy may
achieve the maximum mean survival time within 5 years. However, this may not be the
optimal treatment policy considering that surgery plus chemotherapy is more invasive than
surgery alone and the estimated SI curve is almost horizonal for v in (0,0.3).
To take into account of the side effect of chemotherapy, we may consider a utility measure
U , for example, U = T ∗ − dA, where d is a nonnegative weight denoting the deteriorating
effect of chemotherapy on the survival time; that is, a person may prefer surgery alone if
the additional chemotherapy does not lengthen the survival time by at least d. The SI
curve based on U can be obtained by shifting the SI curve based on T ∗ by w(1 − v) and
hence can be easily estimated. The optimal threshold can be achieved by maximizing the SI
curve based on U . The right panel of Figure 6 shows the corresponding nonparametric and
semiparametric estimates with d = 0.5. The maximum point is achieved at v = 0.32 for the
semiparametric SI curve estimate. This indicates that, considering the c-myc expression
level and the side effect of chemotherapy, the optimal treatment policy may be the one
that assigns patients whose c-myc expression level falls below the 32% percentile to surgery
alone. The maximum point of the nonparametric estimate may be less stable since the
non-smoothness of the curve. We do not see significant difference on either estimate across
v which may due to the small sample size of this dataset. Whether the difference is clinically
important may be worth future investigation with larger clinical trials.
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As we have discussed in Section 1, it is also of interest to assess whether the gender of
the patient may affect the treatment selection. Although we may estimate a separate SI
curve for males and females, the estimate may be unreliable because of the small sample size
in each group. We thus estimated the covariate specific SI curve based on T adjusting for
Z = I(gender=male) using the semiparametric estimator θ˜∗(v|z) by further including Z and
all the two-way and three-way interactions in the proportional hazards model considered
above. The left panel of Figure 7 shows the results. For male patients, the SI curve seems
to be horizontal before v = 0.3 and decline thereafter, while for female patients the SI
curve tends to decrease for v from 0 to 1. This indicates the optimal thresholds treatment
selection should be different for males and females. To obtain the optimal thresholds, the
covariate specific SI curves based on U were also estimated as shown in the right panel of
Figure 7. The estimated optimal threshold is v = 0.25 for males and v = 0.05 for females.
Thus we may want to assign almost all females to surgery plus chemotherapy while assign
male patients whose c-myc expression level fall below the 25% percentile to surgery alone.
6. DISCUSSION
We have proposed the SI curve for the survival time to evaluate the impact of a treatment
selection policy based on Y > yv. Both nonparametric and semiparametric estimators
are derived. We recommend using the nonparametric estimator when it is not necessary
to adjust for covariates because of its robustness. The semiparametric estimators are less
robust, but can be more efficient under the correctly specified model. In addition, they can
easily incorporate covariates in estimation. Whether to use the unadjusted or adjusted SI
curve depends on the specific treatment policy, that is, whether we would like to select the
treatment based on the biomarker alone.
For the semiparametric approach, we have used the standard proportional hazards model
to characterize the relationship between the survival time and the marker and the covariates.
This can be easily adapted to more flexible models. For example, we can use other survival
models, such as the stratified proportional hazards model, the accelerated failure time
model and the transformation model, as long as we can obtain consistent estimators for the
survival distribution. The nonparametric transformation model (Song et al., 2007) may be
an attractive extension as it includes most popular survival models as special cases, such as
the proportional hazards model and the accelerated failure time model. The semiparametric
location model (7) is used only for estimating the conditional distribution function FY |Z .
We can remove this assumption and estimate FY |Z by kernel smoothing method when
the number of covariates is small and the sample size is relatively large, since the kernel
smoothing method may not work well otherwise.
Although the SI curve is proposed based on the restricted mean survival time, it can
be extended to other statistical measures. For example, a utility function that incorporates
notions of cost and quality of life might be employed. Although we have focused on survival
time as outcomes, the approach can be adapted to discrete and continuous outcomes with
minor modifications.
In this paper, we consider SI curves based on a single biomarker. In practice, there
may exist multiple biomarkers. For example, multiple genes may be related to a specific
disease or affect the survival time. An important issue is how to combine these biomarkers
for treatment selection. On the other hand, it may be needed to select among more than
two treatments. These issues will be investigated in our future research.
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Appendix A. ASYMPTOTIC PROPERTIES OF θ(v)
Now we derive the asymptotic properties of θˆ(v) based primarily on empirical process theory.
Let Y be the support of Y and FY (y) = P (Y ≤ y) be the distribution function of Y . We
assume the following regularity conditions:
A. T and C are independent given Y and A;
B. P (X ≥ L,A = 1, Y > yq) > 0 and P (X ≥ L,A = 0, Y < yp) > 0 for some constants
p and q, 0 < p < q < 1;
C. For y ∈ Y and a ∈ {0, 1}, S(a)(u, y) is an absolutely continuous distribution function
of u for u ∈ [0,+∞);
D. FY (y) is continuously differentiable with a positive derivative fY (y) on the interval
[F (−1)(p)− ε, F (−1)(q) + ε] for some ε > 0.
Let Eˆ be the empirical average operator such that Eˆc = n−1
∑n
i=1 ci. Let
Λˆ(a)(t, y) =
∫ t
0
EˆN (a)(ds, y)
EˆR(a)(s, y)
be the Nelson-Aalen estimator of Λ(a)(t, y), a = 0, 1. Using the functional delta method,
we can show the following lemma:
Lemma 1. n1/2
{
Λˆ(a)(t, y)− Λ(a)(t, y)
}
converges to a Gaussian process H(a)(t, y) in [0, L]×
[yp, yq] with mean zero and covariance
cov
{
H(a)(t1, y1),H(a)(t2, y2)
}
= cov
{
ω
(a)
i (t1, y1), ω
(a)
i (t2,y2)
}
,
where
ω
(a)
i (t, y) =
∫ t
0
[
N
(a)
i (du, y)
ER(a)(u, y)
− EN
(a)(du, y)R(a)2i (u, y){
ER(a)(u, y)
}2
]
.
Then, under conditions A–C, applying the functional delta method to the product inte-
gral (van der Vaart and Wellner 2000, chap. 3.9.4.5), we can show the following lemma:
Lemma 2. n1/2
{
Sˆ(a)(t, y)− S(a)(t, y)
}
converges to the Gaussian process −S(a)(t, y)H(a)(t, y)
in [0, L]× [yp, yq].
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Using empirical process theory, we know that the empirical process n1/2{FˆY − FY }
converges to a Gaussian process F. Since θˆ(v) is a composite function of Sˆ(0), Sˆ(1) and FˆY ,
the asymptotic distribution of θˆ(v) is then derived using Lemma 2 and condition D and
using the functional delta method (van der Vaart and Wellner 2000, chap. 3.9) with some
simple algebra.
Theorem 1. n1/2
{
θˆ(v)− θ(v)
}
converges on the interval [p, q] to a Gaussian process
G(v) = −(1− v)
∫ L
0
[
S(1)(t, yv)H(1)(t, yv)
+S(1)(t, yv)
∂Λ(1)(t, yv)
∂y
{
1− Λ(1)(t, yv)
} F(yv)
fY
{
F−1Y (v)
}]dt
−v
∫ L
0
[
S(0)(t, yv)H(0)(t, yv)
+S(0)(t, yv)
∂Λ(0)(t, yv)
∂y
{
1− Λ(0)(t, yv)
} F(yv)
fY
{
F−1Y (v)
}]dt
with mean zero and covariance cov {G(v1),G(v2)} = cov {σ(v1), σ(v2)}, where
σ(v) = −(1− v)
∫ L
0
[
S(1)(t, yv)ω
(1)
i (t, yv)
+S(1)(t, yv)
∂Λ(1)(t, yv)
∂y
{
1− Λ(1)(t, yv)
} I(Yi ≤ yv)
fY
{
F−1Y (v)
}]dt
−v
∫ L
0
[
S(0)(t, yv)ω
(0)
i (t, yv)
+S(0)(t, yv)
∂Λ(0)(t, yv)
∂y
{
1− Λ(0)(t, yv)
} I(Yi ≤ yv)
fY
{
F−1Y (v)
}]dt.
Appendix B. ASYMPTOTIC PROPERTIES OF θ˜(v|z) AND θ˜∗(v|z)
Regularity Conditions. Let Z be the support of Z, τ be a constant such that τ ≥ L,
Wi = (Vi, Ai, Xi,∆i), and
Qbi (β;W, s) = Ri(s)g⊗b(Vi,Zi, Ai) exp
{
βT g(Vi,Zi, Ai)
}
, for b = 0, 1, 2,
where for any vector c, c⊗r = 0, 1, ccT for r = 0, 1, 2, respectively. To derive the asymptotic
properties for θ˜(v|z), we assume the following regularity conditions:
A′. T and C are independent given Y , A and Z;
B′. P (X ≥ L) ≥ P (X ≥ τ) > 0;
C′. For v ∈ (0, 1), z ∈ Z and a = 0, 1, S(t|v, z, a) is an absolutely continuous function of
t for t ∈ [0,+∞);
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D′. Γ (β0) =
∫ τ
0
{
EQ2(β0;W,s)
EQ0(β0;W,s)
− EQ21(β0;W,s)
EQ20(β0;W,s)
}
EdN(s) is positive definite;
E′. For v ∈ (0, 1), z ∈ Z and a = 0, 1, g(v, z, a) is bounded and has uniformly continuous
and bounded partial derivative g˙(v,z, a) = ∂g(v, z, a)/∂v;
F′. E(ZTZ) <∞, E(Y 2) <∞, E(ZZT ) is positive definite;
G′. h(y) is bounded and has first- and second- order bounded derivatives h′(y) and h′′(y)
for y ∈ (−∞,+∞).
The asymptotic properties for θ˜(v|z) and θ˜∗(v|z) are summarized in the following the-
orems.
Theorem 2. Given z ∈ Z, n1/2
{
θ˜(v|z)− θ(v|z)
}
converges to a zero-mean Gaussian
process G∗(v, z) with the covariance given in Appendix B.
Theorem 3. Given z ∈ Z, n1/2
{
θ˜∗(v|z)− θ(v|z)
}
converges to a zero-mean Gaussian
process G#(v, z) on the interval [p, q] with the covariance given in Appendix B.
Derivation of Asymptotic Properties of θ˜(v|z). Under conditions A′–E′, the asymptotic
properties of βˆ, Λˆ0(t) and Sˆ(t|v, z, a) have been shown in Andersen and Gill (1982). Since
θ(v|z) is a composite functional differentiable with respect to S(t|v, z, a), Λ0(t) and β0,
using the functional delta method , n1/2
{
θ˜(v|z)− θ(v|z)
}
converges to a Gaussian process
G∗z(v, z) for v ∈ (p, q) with mean zero. Next we derive the covariance of G∗z(v, z).
The partial likelihood estimating equation can be written as
Uˆ (β;W ) =
∫ τ
0
{
Eˆg(V,Z, A)dN(s)− EˆQ1 (β;Wi, s)
EˆQ0 (β;Wi, s)
EˆdN(s)
}
= 0,
Let Γˆ (β) = ∂Uˆ(β)∂β . Using arguments similar to those in the appendix of Huang and Wang
(2000), we can show that
n1/2
{
βˆ − β0
}
= n−1/2
n∑
i=1
pi(β0;Wi) + op(1), (B.1)
where
pi(β;Wi) = Γ−1 (β) ρ (β;Wi) , and
ρ (β;Wi) =
∫ τ
0
{
g(Vi,Zi, Ai)− EQ1 (β0;Wi, s)
EQ0 (β0;Wi, s)
}{
dNi(s)− Q0i (β0;Wi, s)
EQ0 (β0;Wi, s)
EdN(s)
}
.
The Breslow estimator for the cumulated baseline hazard can be written as
Λˆ0(t) =
∫ t
0
EˆdN(s)
EˆQ0 (β;Wi, s)
.
Using the functional delta method, we can show that n1/2
{
Sˆ(t|u, z, a)− S(t|u, z, a)
}
con-
verges to a Gaussian process with mean zero. With the functional Taylor expansion,
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straightforward algebra leads to
n1/2
{
Λˆ0(t)− Λ0(t)
}
= n−1/2
n∑
i=1
δ(t, β0,Wi)
−
∫ t
0
EQT1 (β0;Wi, s)EdN(s)
E2Q0 (β0;Wi, s)
n1/2
{
βˆ − β0
}
+ op(1),(B.2)
and
n1/2
{
Sˆ(t|u, z, a)− S(t|u, z, a)
}
= −S(t|u, z, a) exp{βT0 g (u,z, a)}n1/2 {Λˆ0(t)− Λ0(t)}
−S(t|u, z, a) exp{βT0 g (u,z, a)}Λ0(t)gT (u,z, a)n1/2 {βˆ − β0}
+op(1), (B.3)
where
δ(t, β,Wi) =
∫ t
0
dNi(s)EQ0 (β;Wi, s)−Ri(s) exp
{
βT g (Vi,Zi, Ai)
}
EdN(s)
E2Q0 (β;Wi, s)
.
Substituting (B.1) and (B.2) in (B.3), we have
n1/2
{
Sˆ(t|u, z, a)− S(t|u, z, a)
}
= n−1/2
n∑
i=1
ξ(β0, t, u, z, a,Wi) + op(1),
where
ξ(β, t, u, z, a,Wi) = −S(t|u, z, a) exp
{
βT g (u,z, a)
}
×
(
δ(t, β,Wi)−
{∫ t
0
EQT1 (β;Wi, s)EdN(s)
E2Q0 (β;Wi, s)
− Λ0(t)gT (u,z, a)
}
pi(β;Wi)
)
.
Therefore
n1/2
{
θˆ(v|z)− θ(v|z)
}
=
n∑
i=1
∫ 1
v
∫ L
0
n1/2
{
Sˆ(t|u,z, 1)− S(t|u, z, a)
}
dtdu
+
∫ v
0
∫ L
0
n1/2
{
Sˆ(t|u, z, 1)− S(t|u,z, a)
}
dtdu+ op(1)
= n1/2
n∑
i=1
µi(v; z) + op(1),
where
µi(v; z) =
∫ 1
v
∫ L
0
ξ(β, t, u, z, 1, Xi,Zi, Ai)dtdu+
∫ v
0
∫ L
0
ξ(β, t, u, z, 0, Xi,Zi, Ai)dtdu.
Hence cov{G∗(v1;z),G∗(v2;z)} =cov{µ(v1; z), µ(v2;z)} = Σ(v1,v2;z) for v1, v2 ∈ (p, q).
An estimator of the variance var{µ(v; z)} = Σ(v, v; z) is
Σˆ(v, v;z) = n−1
n∑
i=1
{
µˆi(v;z)− µˆ(v; z)
}2
, (B.4)
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where µˆ(v;z) = n−1
∑n
i=1 µˆi(v;z),
µˆi(v; z) =
∫ 1
v
∫ L
0
ξˆ(βˆ, t, u, z, 1, Xi,Zi, Ai)dtdu+
∫ v
0
∫ L
0
ξˆ(βˆ, t, u, z, 0, Xi,Zi, Ai)dtdu,
ξˆ(β, t, u, z, 1, Xi,Zi, Ai) = −Sˆ(t|u,z, a) exp
{
βT g (u,z, a)
}
×
(
δˆ(t, β,Wi)−
{∫ t
0
EˆQT1 (β;Wi, s) EˆdN(s)
Eˆ2Q0 (β;Wi, s)
− Λˆ0(t)gT (u, z, a)
}
pˆi(β0;Wi)
)
,
δˆ(t, β,Wi) =
∫ t
0
dNi(s)EˆQ0 (β;Wi, s)−Ri(s) exp
{
βT g (Vi,Zi, Ai)
}
EˆdN(s)
Eˆ2Q0 (β;Wi, s)
,
pˆi(β;Wi) = Γˆ−1 (β) ρˆ (β;Wi) ,
ρˆ (β;Wi) =
∫ τ
0
{
g(Vi,Zi, Ai)− EˆQ1 (β0;Wi, s)
EˆQ0 (β0;Wi, s)
}{
dNi(s)− Q0i (β0;Wi, s)
EˆQ0 (β0;Wi, s)
EˆdN(s)
}
,
Γˆ (β) =
∫ τ
0
{
EˆQ2 (β;W, s)
EˆQ0 (β;W, s)
− EˆQ
2
1 (β;W, s)
EˆQ20 (β;W, s)
}
EˆdN(s).
Derivation of Asymptotic Properties of θ˜∗(v|z). Now, we consider the asymptotic
properties of θ˜∗(v|z). We only need to show that n1/2
(
β˜ − β0
)
is asymptotically normal
and then use similar proofs as those for θ˜(v|z). Let Vˆi = hˆ(Yi; γˆ), and Wˆi =
(
Vˆi, Ai, Xi,∆i
)
.
First, under condition F′, by the Slutsky theorem,
n1/2 (γˆ − γ0) =
(
n−1
n∑
i=1
ZiZ
T
i
)−1
n−1/2
n∑
i=1
Zi
(
Yi − γ0ZTi
)
(B.5)
converges in distribution to a zero-mean normal random variable. Let N (γ0) be a compact
neighborhood of γ0. By the functional central limit theorem,
n1/2
[
hˆ(y − γT z, γ)− Eh{y + γT (Z − z)− γ0Z}]
converges to a mean zero Gaussian process on (y,γ) ∈ Y × N (γ0). It follows from the
equicontinuity of the foregoing process and the consistency of γˆ that
sup
y∈Y
∣∣∣n1/2 [hˆ(y − γˆT z, γˆ)− Eh{y + γˆT (Z − z)− γ0Z}]
−n1/2
[
hˆ(y − γT0 z, γˆ)− h
{
y − γT0 Z
}]∣∣∣ = op(1).
This implies that
n1/2
{
hˆ(y − γˆT z, γˆ)− h(y − γT0 z)
}
= n1/2
{
hˆ(y − γT0 z, γˆ)− h(y − γT0 z)
}
+n1/2
{
Eh
{
y + γˆT (Z − z)− γ0Z
}− h(y − γT0 z)}+ op(1) (B.6)
uniformly for y ∈ Y. By a Taylor series expansion, under condition G′, the second term in
(B.6) can be written as
h′(y)
{
ET (Z)− z}n−1/2 (γˆ − γ0) + op(1)
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uniformly for y ∈ Y. This, together with (B.5), implies that
n1/2
{
hˆ(y − γˆT z, γˆ)− h(y − γT0 z)
}
= n−1/2
n∑
i=1
[{
I
(
Yi − γT0 Zi ≤ y − γT0 z
)− h(y − γT0 z)}
+h′(y − γT0 z) {E(Z)− z}T
{
E(ZZT )
}−1
Zi
(
Yi − ZTi γ0
)]
+ op(1) (B.7)
uniformly for y ∈ Y. With arguments similar to those in Song and Pepe (2004), under
condition E′,
n1/2
{
Uˆ(β; Wˆ )− Uˆ(β;W )
}
= n1/2
∫ τ
0
[
EˆQ∗0 (β;Wi, s) dNi(s)
−
{
EˆQ∗2 (β;Wi, s)
EˆQ0 (β;Wi, s)
− EˆQ1 (β;Wi, s) EˆQ
∗T
1 (β;Wi, s)
Eˆ2Q0 (β;Wi, s)
}
EˆdN(s)
]
+ op(1),
where
Q∗bi (β; s,Wi) = Q
#
bi (β;Wi, s)
(
Vˆi − Vi
)
,
Q#0i (β;Wi, s) = g˙(Vi,Zi, Ai),
Q#1i (β;Wi, s) = Ri(s)g(Vi,Zi, Ai) exp
{
βT g(Vi,Zi, Ai)
}
g˙(Vi,Zi, Ai),
Q#2i (β;Wi, s) = Ri(s) {I + g(Vi,Zi, Aig˙(Vi,Zi, Ai))β} exp
{
βT g(Vi,Zi, Ai)
}
.
Using (B.7), we have
n1/2EˆQ∗b (β; s,Wi) =
1
2
n−3/2
n∑
i=1
n∑
j=1
ηb (Wi,Wj , s) + op(1),
where
ηb (β;Wi,Wj , s) = Q
#
bi (β;Wi, s)
[
I(Yj − γT0 Zj ≤ Yi − γT0 Zi)− h(Yi − γT0 Zi)
+h′(Yi − γT0 Zi) {E(Z)− Zi}T
{
E(ZZT )
}−1
Zj
(
Yj − γ0ZTj
)]
+Q#bi (β;Wj , s)
[
I(Yi − γT0 Zi ≤ Yj − γT0 Zj)− h(Yj − γT0 Zj)
+h′(Yj − γT0 Zj) {E(Z)− Zj}T
{
E(ZZT )
}−1
Zi
(
Yi − γT0 Zi
)]
.
Note E {ηb (β;Wi,Wj , s)} = 0. It is simple to show that
1
2
n−3/2
n∑
i=1
n∑
j=1
ηb (β;Wi,Wj , s) =
2
n(n− 1)
n∑
i=1
∑
j>1
ηb (β;Wi,Wj , s) + op(1).
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The first term on the right hand side is a U-process and can be rewritten as
n1/2
n∑
i=1
η∗b (β;Wi, s) +
1
n(n− 1)
n∑
i 6=j
η#b (β;Wi,Wj , s), (B.8)
where
η∗b (β;w, s) = E {ηb (β;w,W2, s)} ,
η#b (β;Wi,Wj , s) = ηb (β;Wi,Wj , s)− η∗b (β;Wi, s)− η∗b (β;Wj , s).
The second term in (B.8) is a degenerate U-process. Under conditions E′ and G′, the class
of functions {η#b (β, ·, ·, s) : β ∈ N (β0), s ∈ [0, τ ]} is Euclidean by Lemma 22(ii) in Nolan
and Pollard (1987) and Lemma (2.14) in Pakes and Pollard (1989). With an application of
Theorem 9 in Nolan and Pollard, the second term in (B.8) is equal to op(1). Hence
n1/2EˆQ∗b (β; s, Vi,Zi, Ai) = n
1/2
n∑
i=1
η∗b (β;Wi, s) + op(1).
Now using a functional Taylor expansion, we have
n1/2
{
Uˆ(β; Wˆ )− Uˆ(β;W )
}
= n−1/2
n∑
i=1
ζ (β;Wi) + op(1),
where
ζ (β;Wi) =
∫ τ
0
(
η∗0 (β;Wi, s) dNi(s)
−
[
η∗2i(β;Wi, s)
EQ0 (β;Wi, s)
− Eη
∗
2 (β;Wi, s) [Q0i(β;Wi, s)− E {Q0i(β;Wi, s)}]
E2Q0 (β;Wi, s)
−Eη
∗T
1 (β;Wi, s) [Q1i (β;Wi, s)− EQ1 (β;Wi, s)] + EQ1 (β;Wi, s) η∗1i(β;Wi, s)
E2Q0 (β;Wi, s)
+
2EQ1 (β;Wi, s)Eη∗
T
1 (β;Wi, s) [Q0i (β;Wi, s)− EQ0 (β;Wi, s)]
E3Q0 (β; s, Vi,Zi, Ai)
]
EdN(s)
)
.
Also with a functional Taylor expansion, we have
n1/2
{
Uˆ(β;W )− U (β)
}
= n−1/2
n∑
i=1
ρ (β;Wi) + op(1).
Hence
n1/2
{
Uˆ(β; Wˆ )− U (β)
}
= n1/2
{
Uˆ(β; Wˆ )− Uˆ (β;W )
}
+ n1/2
{
Uˆ(β;W )− U (β)
}
= n−1/2
n∑
i=1
{ζ (β;Wi) + ρ (β;Wi)}+ op(1).
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Then the consistency and asymptotical normality of β˜ follows by arguments similar to
those in the appendix of Huang and Wang (2000), and we obtain the following asymptotic
expansion:
n1/2
{
β˜ − β0
}
= n−1/2
n∑
i=1
pi∗(β0;Wi) + op(1),
where pi∗(β0;Wi) = Γ−1 (β0) {ζ (β;Wi) + ρ (β;Wi)}; that is, n1/2
{
β˜ − β0
}
is normal with
mean zero and asymptotic variance var {pi∗(β0;Wi)}. The Breslow estimator for Λ0(t) can
be written as
Λ˜0(t; βˆ, Wˆi) =
∫ t
0
EˆdN(s)
EˆQ0
(
βˆ; Wˆi, s
) .
With similar arguments to those for n1/2
{
Uˆ(β; Wˆ )− Uˆ(β;W )
}
, we can show that
n1/2
{
Λ˜0(t;β, Wˆi)− Λ˜0(t;β,Wi)
}
= n−1/2
n∑
i=1
κ (t;β,W ) + op(1),
where
κ (t;β,W ) =
−
∫ t
0
[
η∗1 (β;Wi, s)
E2Q0 (β;W, s)
− 2Eη
∗
1 (β;W, s) {Q0i (β;Wi, s)− EQ0 (β;Wi, s)}
Eˆ3Q0 (β;Wi, s)
]
EdN(s).
Also with a functional Taylor expansion, we have
n1/2
{
Λ˜0(t;β,Wi)− Λ0(t)
}
= n−1/2
n∑
i=1
δ(t, β,Wi) + op(1).
Therefore
n1/2
{
Λ˜0(t;β, Wˆi)− Λ0(t)
}
= n1/2
{
Λ˜0(t;β, Wˆi)− Λ˜0(t;β,Wi)
}
+ n1/2
{
Λ˜0(t;β,Wi)− Λ0(t)
}
= n−1/2
n∑
i=1
(
κ (β;W ) +
∫ t
0
dNi(s)−Ri(s) exp
{
βT0 g (Vi,Zi, Ai)
}
E [dN(s)]
EQ0 (β;Wi, s)
)
+ op(1).
With a functional Taylor expansion, we have
n1/2
{
Λ˜0(t; β˜,Wi)− Λ0(t)
}
= n−1/2
n∑
i=1
δ˜(t, β,Wi)−
∫ t
0
EQ1 (β;Wi, s)EdN(s)
E2Q0 (β;Wi, s)
n1/2
{
β˜ − β0
}
+ op(1),
where
δ˜(t, β,Wi) =
(
κ (β;W ) +
∫ t
0
dNi(s)−Ri(s) exp
{
βT0 g (Vi,Zi, Ai)
}
E [dN(s)]
EQ0 (β;Wi, s)
)
.
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Then using arguments similar to those for θ˜(v|z), we can show that
n1/2
{
θ˜∗(v|z)− θ(v|z)
}
= n1/2
n∑
i=1
µ∗(v; z) + op(1),
where
µ∗(v;z) =
∫ 1
v
∫ L
0
ξ˜(β, t, u, z, 1, Xi,Zi, Ai)dtdu+
∫ v
0
∫ L
0
ξ˜(β, t, u, z, 0, Xi,Zi, Ai)dtdu,
where ξ˜(β, t, u, z, a,Wi) is obtained by replacing δ(t, β,Wi) by δ˜(t, β,Wi) and pi(β0;Xi,Zi, Ai)
by pi∗(β0;Xi,Zi, Ai), that is,
ξ˜(β, t, u, z, a,Wi) = S(t|u, z, a) exp
{
βT0 g (u,z, a)
}
×
δ(t, β,Wi)

∫ t
0
EQ1 (β;Wi, s)EdN(s)
E2Q0
(
βˆ;Wi, s
) − Λ0(t)g (u,z, a)
pi∗(β0;Xi,Zi, Ai)
 .
Hence n1/2
{
θ˜∗(v|z)− θ(v|z)
}
converges to a Gaussian process G#(v, z) with mean zero
and covariance cov{G#(v1; z),G#(v2;z)} = cov{µ∗(v1; z), µ∗(v2; z)} for v1, v2 ∈ (p, q).
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Fig. 1. Kaplan-Meier estimates of disease progression free survival by treatment and c-myc level
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Fig. 2. Example of SI curves
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(b) Male
Fig. 3. Kaplan-Meier estimates of disease progression free survival by treatment and c-myc level for
different genders.
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Fig. 4. True SI curve in simulation. Solid line, proportional hazards modal; dashed line, Gamma
survival distribution.
Hosted by The Berkeley Electronic Press
26 X. Song and X.H. Zhou
0.0 0.2 0.4 0.6 0.8 1.0
1
2
3
4
5
v
q
(v
)
z=−1
z= 0
z= 1
Fig. 5. True covariate specific SI curve in simulation.
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Fig. 6. Estimated SI curve for ECOG data. Left panel is based on 5 year restricted survival time
T ∗, right panel is based on the utility function U = T ∗ − 0.5A. Nonparametric estimate θˆ, solid
curve; semiparametric estimate θ˜, dotted curve. 95% confidence bands are shown with the outer
curves, 95% pointwise confidence intervals are shown with the intermediate curves, the estimates
themselves are shown with the center curves.
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(a) Female
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(b) Male
Fig. 7. Estimated SI curves adjusted for gender for ECOG data. Left panel is based on 5 year
restricted survival time T ∗, right panel is based on the utility function U = T ∗−0.5A. 95% confidence
bands are shown with the outer curves, 95% pointwise confidence intervals are shown with the
intermediate curves, the estimates themselves are shown with the center curves.
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